Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

Clinical trial NCT03240861 · TERMINATED

Trial details

NCT number: NCT03240861
Sponsor: Jonsson Comprehensive Cancer Center
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

HLA-A*0201 Positive Cells Present Locally Advanced Malignant Neoplasm NY-ESO-1 Positive Unresectable Malignant Neoplasm Sarcoma

Start date: 2017-07-26
Primary completion: 2023-10-19
Enrollment: 5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.